RxSight Inc (RXST)
45.05
+0.89
(+2.02%)
USD |
NASDAQ |
Nov 15, 16:00
45.05
0.00 (0.00%)
After-Hours: 20:00
RxSight Research and Development Expense (TTM): 32.50M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 32.50M |
| June 30, 2024 | 30.76M |
| March 31, 2024 | 29.87M |
| December 31, 2023 | 29.05M |
| September 30, 2023 | 28.39M |
| June 30, 2023 | 27.68M |
| March 31, 2023 | 26.47M |
| December 31, 2022 | 25.98M |
| Date | Value |
|---|---|
| September 30, 2022 | 25.22M |
| June 30, 2022 | 24.20M |
| March 31, 2022 | 24.58M |
| December 31, 2021 | 24.50M |
| September 30, 2021 | 23.86M |
| June 30, 2021 | 24.28M |
| March 31, 2021 | 22.80M |
| December 31, 2020 | 21.93M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
21.93M
Minimum
Dec 2020
32.50M
Maximum
Sep 2024
26.38M
Average
25.60M
Median
Research and Development Expense (TTM) Benchmarks
| Tandem Diabetes Care Inc | 189.28M |
| Perspective Therapeutics Inc | 28.53M |
| Retractable Technologies Inc | 0.654M |
| Xtant Medical Holdings Inc | 2.145M |
| Catheter Precision Inc | 0.219M |